Chengdu shengnuo Biotechnology Co., Ltd.
(hereinafter referred to as “Shengnuo Biotechnology “) is a high-tech enterprise with the core technology of peptide synthesis and modification, with advanced and efficient peptide drug process research and development and large-scale production capacity.
The company’s main business is independent research and development, production and sales of peptide API and preparation products with large market capacity and strong competitiveness at home and abroad.
Meanwhile, relying on its technical advantages in the field of peptide drug research and development and large-scale production, the company provides domestic and foreign pharmaceutical enterprises with multi peptide innovative pharmaceutical research services, customized production services of peptide products and peptide drug production technology Technology transfer services.
twenty-one Since the beginning of the 20th century, with the rise of generic drugs and the advancement of global division of medicine, the disadvantages of traditional peptide API production areas in Europe and the United States have become increasingly prominent in terms of cost.
China, India and other emerging market countries have cut into the peptide generic drug market from R & D API, and gradually take the initiative by virtue of cost advantages, which has greatly promoted the development of peptide drug industry.
At present, China has become a peptide pharmaceutical industry API is a big exporting country, accounting for more than 30% of the global peptide API market.
In the future, there will be great opportunities in the field of new varieties of domestic peptide preparations. At present, nearly half of the peptide drugs on the market in the world have not yet been listed in China.
The utilization rate of the top ten peptide products in the global sales volume in China is still relatively low. Peptide drugs have broad market space in the domestic market, such as cancer and diabetes, and have great potential for development.
The number of approved preparations and dosage forms of peptide drug enterprises can reflect the long-term competitiveness of enterprises in the industry.
On the basis of self-produced peptide API,Shengnuo Biotechnology has successfully developed 7 varieties of peptide preparations, and obtained 11 production approval documents in China. The number of varieties and dosage form approval documents ranked among the top three in China, reflecting the comprehensive strength of the company.
In terms of R & D, there are 5 core technicians of Shengnuo Biotechnology , all of whom have rich theoretical and practical experience in peptide R & D. Among them, Mr. Wen Yongjun, chief scientist and chairman of the board of directors of the company, is one of the earliest experts in the field of polypeptide drugs in China.
He once presided over the development of thymopentin, the first polypeptide drug approved by the state and obtained the new drug certificate in China, and presided over the completion of the first domestic imitation of thymic method.
He has successively won the “outstanding contribution award of polypeptide application” and the “third prize” of the 10th and 12th International polypeptide conference “Outstanding talent award” of the second national peptide drug R & D and large-scale production frontier technology exchange conference was selected as Sichuan Tianfu pioneer talent project in 2018.
Other core personnel have more than 15 years of research and practical experience in peptide synthesis, and the team members have won the title of top innovation and entrepreneurship team of Sichuan Province for introducing high-level talents